Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Progression Survival Time According to Time-of-Day (ToD) of Administration of Immunochemotherapy for Advanced Non-small Cell Lung Cancer: A Phase III Randomized Control Trial

NCT05549037 is registered in ClinicalTrials.gov with Hunan Province Tumor Hospital as lead sponsor.

NCT NCT05549037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05549037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Progression Survival Time According to Time-of-Day (ToD) of Administration of Immunochemotherapy for Advanced Non-small Cell Lung Cancer: A Phase III Randomized Control Trial
Lead sponsor
Hunan Province Tumor Hospital
Phase
Phase 3
Overall status
Completed
Start date
September 23, 2022
Completion date
April 30, 2026
Enrollment
210 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer